|
An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and challenges with the FDA.
|
 |
|
Backed by the venture portions of Eli Lily and Eisai, Excalipoint will look to progress the development of its six-strong TCE therapy pipeline.
|
|
|
A Gilead executive highlights limited investment in innovation against the need to speed up access to ATMPs.
|
|
|
Health secretary Wes Streeting is considering expanding the existing schedule to age groups beyond infants, such as teenagers.
|
|
|
At Advanced Therapies, investors noted that early planning, adaptability and building trust will help a biotech startup succeed.
|
|
